{
    "title": "114_s131",
    "content": "The Act is known as the \"Fair And Immediate Release of Generic Drugs Act\" or the \"FAIR Generics Act\". It includes amendments regarding the 180-day exclusivity period for first applicants. The \"Fair And Immediate Release of Generic Drugs Act\" or the \"FAIR Generics Act\" amends the Federal Food, Drug, and Cosmetic Act regarding the 180-day exclusivity period for first applicants. It defines a \"first applicant\" as an applicant who submits a substantially complete application on the first day a certification is submitted for drug approval. The \"FAIR Generics Act\" amends the Federal Food, Drug, and Cosmetic Act regarding the 180-day exclusivity period for first applicants. A first applicant must submit a substantially complete application and maintain a certification for the drug. The applicant must not have entered into a disqualifying agreement and must satisfy all requirements described in the clause. The \"FAIR Generics Act\" requires first applicants to maintain certifications for unexpired patents and avoid patent infringement actions within a specified period. The \"FAIR Generics Act\" requires first applicants to maintain certifications for unexpired patents and avoid patent infringement actions within a specified period. If an action was brought within the specified time period, it must either be withdrawn or dismissed without a decision on patent validity and infringement, or the applicant must obtain a court decision declaring the patent invalid or not infringed. The \"FAIR Generics Act\" mandates that first applicants must hold certifications for unexpired patents and refrain from patent infringement actions within a set timeframe. If an infringement action is initiated, it must be resolved by withdrawing, dismissing without a decision, or obtaining a court ruling on patent validity or infringement. Amendments made by the Act apply solely to applications filed under section 505(j). The \"FAIR Generics Act\" mandates that first applicants must hold certifications for unexpired patents and refrain from patent infringement actions within a set timeframe. The amendments made by the Act apply only to applications filed under section 505(j) of the Federal Food, Drug, and Cosmetic Act. SEC. 3. 180-DAY EXCLUSIVITY PERIOD AMENDMENTS REGARDING AGREEMENTS TO DEFER COMMERCIAL MARKETING. Amendments to the Federal Food, Drug, and Cosmetic Act include limitations on agreements to defer commercial marketing dates, specifically addressing agreements between first applicants and holders of drug applications or patent owners for the 180-day exclusivity period. The 180-day exclusivity period agreement prohibits the applicant from seeking early approval or marketing their drug before a certain date. The subclause agreement prohibits an applicant from seeking approval or marketing their drug before the expiration of the 180-day exclusivity period awarded to another applicant. The agreement limits the acceleration of seeking approval or marketing a drug before the expiration of the exclusivity period. The agreement restricts the early approval and marketing of a drug before the exclusivity period expires. The holder of an abbreviated application must submit a notification to the FDA including the text or detailed description of any agreement related to early drug approval restrictions. The holder of an abbreviated application must submit a notification to the FDA within 10 business days of executing an agreement related to early drug approval restrictions. Information filed with the Secretary is exempt from disclosure and can only be made public if relevant to administrative or judicial actions. The paragraph discusses amendments to Section 301(e) of the Federal Food, Drug, and Cosmetic Act and Section 271(e) of title 35, United States Code regarding patent infringement. The exclusive remedy for patent infringement related to drug approval restrictions is specified within a 45-day period. The amendment made by subsection (a)(1) of the Food, Drug, and Cosmetic Act applies to specific applications and agreements executed after the enactment of the Act. The amendments made by subsection (a)(1) of the Food, Drug, and Cosmetic Act only apply to agreements executed after the enactment of the Act."
}